Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma

Trial Profile

Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Endometrial cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 18 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top